# Pip-Tryptamine

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Pip-Tryptamine
> Markdown URL: https://mediated.wiki/source/Pip-Tryptamine.md
> Source: https://en.wikipedia.org/wiki/Pip-Tryptamine
> Source revision: 1356147998
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

{{Lowercase title}}
{{Infobox drug
| drug_name = pip-Tryptamine
| image = Pip-Tryptamine.svg
| image_class = skin-invert-image
| width = 200px
| image2 = pip-T 3D.png
| image_class2 = bg-transparent
| width2 = 225px

<!-- Clinical data -->
| pronounce = 
| tradename = 
| Drugs.com = 
| MedlinePlus = 
| licence_CA = 
| licence_EU = 
| DailyMedID = 
| licence_US = 
| pregnancy_AU = 
| pregnancy_category = 
| dependency_liability = 
| addiction_liability = 
| routes_of_administration = 
| class = [Serotonin receptor modulator](/source/Serotonin_receptor_modulator)
| ATC_prefix = None
| ATC_suffix = 

<!-- Legal status -->
| legal_status = 

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| metabolites = 
| onset = 
| elimination_half-life = 
| duration_of_action = 
| excretion = 

<!-- Identifiers -->
| CAS_number = 26628-87-5
| CAS_supplemental = 
| PubChem = 33560
| PubChemSubstance = 
| IUPHAR_ligand = 
| DrugBank = 
| ChemSpiderID = 30961
| UNII = 
| KEGG = 
| ChEBI = 
| ChEMBL = 2138465
| NIAID_ChemDB = 
| PDB_ligand = 
| synonyms = 3-(2-Piperidinoethyl)indole; ''N''-Piperidyltryptamine; ''N'',''N''-Piperidyltryptamine; Piperidinyltryptamine; Piperidinotryptamine; PIT; ''N'',''N''-Pentamethylenetryptamine

<!-- Chemical data -->
| IUPAC_name = 3-(2-piperidin-1-ylethyl)-1''H''-indole
| C=15 | H=20 | N=2
| SMILES = C1CCN(CC1)CCC2=CNC3=CC=CC=C32
| StdInChI = 1S/C15H20N2/c1-4-9-17(10-5-1)11-8-13-12-16-15-7-3-2-6-14(13)15/h2-3,6-7,12,16H,1,4-5,8-11H2
| StdInChIKey = PJVCNRSWJSLGCV-UHFFFAOYSA-N
}}

'''pip-Tryptamine''' ('''pip-T'''), also known as '''''N'',''N''-pentamethylenetryptamine''', '''''N'',''N''-piperidyltryptamine''', or '''3-(2-piperidinoethyl)indole''', is a [serotonin receptor modulator](/source/serotonin_receptor_modulator) and possible [serotonergic psychedelic](/source/serotonergic_psychedelic) of the [tryptamine](/source/substituted_tryptamine) family.<ref name="Nichols2018">{{cite book | vauthors = Nichols DE | chapter = Chemistry and Structure–Activity Relationships of Psychedelics | title = Behavioral Neurobiology of Psychedelic Drugs | journal = Current Topics in Behavioral Neurosciences | series = Curr Top Behav Neurosci | volume = 36 | issue = | pages = 1–43 | date = 2018 | pmid = 28401524 | doi = 10.1007/7854_2017_475 | isbn = 978-3-662-55878-2 | url = | quote = A systematic study of the effect of N-alkylation on tryptamine receptor affinities was reported by McKenna et al. (1990). N-alkylated tryptamines were examined with no ring substituents, a 5-methoxy, or 4-hydroxy group. Highest affinities (4–30 nM) for displacement of [125I]DOI from rat cortical homogenate were observed with N,N-dimethyl, N,N-diethyl, N-methyl-N-isopropyl, and N,N-diisopropyl substituents. An affinity of 39 nM was reported for 4-OH-N,N-di(sec-butyl) tryptamine, but the affinity of 4-OH-N,N-diisobutyltryptamine was only 260 nM. Tethering the dialkyl groups into a heterocyclic ring gave mixed results; N-pyrrolidyl had an affinity similar to N,N-dimethyltryptamine (110 vs. 75 nM, respectively), but the affinity for the N-piperidyl was much lower, at 760 nM.}}</ref><ref name="TiHKAL">{{cite book | author1 = [Alexander T. Shulgin](/source/Alexander_T._Shulgin) | author2 = [Ann Shulgin](/source/Ann_Shulgin) | chapter = #52. PYR-T TRYPTAMINE, N,N-TETRAMETHYLENE; INDOLE, 3-[2-(1-PYRROLIDYL)ETHYL]; PYRROLIDINE, 1-[2-(3-INDOLYL)ETHYL]; N,N-TETRAMETHYLENETRYPTAMINE; 1-[2-(1H-INDOL-3-YL)ETHYL]PYRROLIDINE; 1-[2-(1-PYRROLIDYL)ETHYL]INDOLE; "PYRROLIDYLTRYPTAMINE" | pages = 577–578 | chapter-url = https://erowid.org/library/books_online/tihkal/tihkal52.shtml | title = PiHKAL: A Chemical Love Story | date = 1991 | publisher = Transform Press | edition = 1st | location = Berkeley, CA | isbn = 978-0-9630096-0-9 | oclc = 25627628 | url = https://books.google.com/books?id=O8AdHBGybpcC | quote = EXTENSIONS AND COMMENTARY: First of all, the name pyr-T, which is an abbreviation for “pyrrolidinyltryptamine,” is out-and-out wrong. There is just one single nitrogen at the end of the tryptamine chain and it cannot be claimed by both halves of the name. It is intrinsic to the name pyrrolidine as well as to the name tryptamine. This is why the name is in quotation marks. This drug has occasionally been called PT in the popular literature, but choosing to spell it out as pyr-T allows a parallel code to be used with the piperidine and morpholine analogues. These two analogues are both described in the literature. The piperidine material (pip-T) is made via the glyoxylamide (mp 182-183 °C) which is reduced with LAH to the target amine (mp 149-150 °C, HC1 salt 220-221 °C). The morpholine analogue (mor-T) also came to be via the glyoxylamide (mp 187-188 °C) and the reduction to the amine which can be an oil, but which has been reported to have a mp 145- 147 °C. The only trials I know of with either of these is with mor-T which, as the fumarate salt, had no effects at all upon the i.m. injection of a 30 milligram bolus. Actually, this neat trilogy of heterocyclics, the pyrrolidine ring, the piperidine ring, and the morpholine ring, have been the chemist's favorite for many years. Leaf through the “Known Tryptamines” appendix, and see how often you see stretched between the nitrogen substituents the phrases: [...]}}</ref><ref name="McKennaRepke1990">{{cite journal | vauthors = McKenna DJ, Repke DB, Lo L, Peroutka SJ | title = Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes | journal = Neuropharmacology | volume = 29 | issue = 3 | pages = 193–198 | date = March 1990 | pmid = 2139186 | doi = 10.1016/0028-3908(90)90001-8 | url = | doi-access = free }}</ref><ref name="AbieroRyuBotanas2020">{{cite journal | vauthors = Abiero A, Ryu IS, Botanas CJ, Custodio RJ, Sayson LV, Kim M, Lee HJ, Kim HJ, Seo JW, Cho MC, Lee KW, Yoo SY, Jang CG, Lee YS, Cheong JH | title = Four Novel Synthetic Tryptamine Analogs Induce Head-Twitch Responses and Increase 5-HTR2a in the Prefrontal Cortex in Mice | journal = Biomol Ther (Seoul) | volume = 28 | issue = 1 | pages = 83–91 | date = January 2020 | pmid = 31230432 | pmc = 6939696 | doi = 10.4062/biomolther.2019.049 | url = }}</ref><ref name="BarlowKhan1959">{{cite journal | vauthors = Barlow RB, Khan I | title = Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations | journal = Br J Pharmacol Chemother | volume = 14 | issue = 1 | pages = 99–107 | date = March 1959 | pmid = 13651585 | pmc = 1481812 | doi = 10.1111/j.1476-5381.1959.tb00934.x | url = }}</ref><ref name="Cami-KobeciSlatfordWhittlesey2005">{{cite journal | vauthors = Cami-Kobeci G, Slatford PA, Whittlesey MK, Williams JM | title = N-Alkylation of phenethylamine and tryptamine | journal = Bioorg Med Chem Lett | volume = 15 | issue = 3 | pages = 535–537 | date = February 2005 | pmid = 15664808 | doi = 10.1016/j.bmcl.2004.11.050 | url = | quote = We were pleased to find that reaction of tryptamine (12) with the appropriate diol (16, 23 and 24) resulted in good conversion to the corresponding pyrrolidine 25, and piperidine 26, and in reasonable isolated yield into azepane 27 (Scheme 6).}}</ref> It is the [derivative](/source/chemical_derivative) of [tryptamine](/source/tryptamine) in which the [amine](/source/amine) has been [cyclized](/source/cyclic_compound) into a [piperidine](/source/piperidine) [ring](/source/ring_(chemistry)).<ref name="Nichols2018" /><ref name="TiHKAL" /><ref name="McKennaRepke1990" />

==Use and effects==
pip-T was only briefly mentioned by [Alexander Shulgin](/source/Alexander_Shulgin) in his book ''[TiHKAL](/source/TiHKAL)'' (''Tryptamines I Have Known and Loved'').<ref name="TiHKAL" /> Its properties and effects were not described.<ref name="TiHKAL" />

==Interactions==
{{See also|Psychedelic drug#Interactions|Trip killer#Serotonergic psychedelic antidotes}}

==Pharmacology==
===Pharmacodynamics===
The [affinities](/source/affinity_(pharmacology)) ({{Abbrlink|IC<sub>50</sub>|half-maximal inhibitory concentration}}) of pip-tryptamine for [serotonin receptor](/source/serotonin_receptor)s were 600{{nbsp}}nM for the [serotonin](/source/serotonin) [5-HT<sub>1A</sub> receptor](/source/5-HT1A_receptor), 760{{nbsp}}nM for the serotonin [5-HT<sub>2A</sub> receptor](/source/5-HT2A_receptor), and 1,250{{nbsp}}nM for the serotonin [5-HT<sub>2B</sub> receptor](/source/5-HT2B_receptor), whereas other serotonin receptors were not reported.<ref name="Nichols2018" /><ref name="McKennaRepke1990" /> The affinity of pip-T for the serotonin 5-HT<sub>2A</sub> receptor was about 10-fold lower than that of [dimethyltryptamine](/source/dimethyltryptamine) (DMT) and was about 7-fold lower than that of [pyr-tryptamine](/source/pyr-tryptamine) (pyr-T; ''N'',''N''-pyrrolidinyltryptamine).<ref name="McKennaRepke1990" /> Pip-T is a [serotonin receptor agonist](/source/serotonin_receptor_agonist) in the rat uterus with similar [potency](/source/potency_(pharmacology)) as DMT, but showed 20-fold lower potency than DMT in the rat fundus strip.<ref name="BarlowKhan1959">{{cite journal | vauthors = Barlow RB, Khan I | title = Actions of some analogues of tryptamine on the isolated rat uterus and on the isolated rat fundus strip preparations | journal = Br J Pharmacol Chemother | volume = 14 | issue = 1 | pages = 99–107 | date = March 1959 | pmid = 13651585 | pmc = 1481812 | doi = 10.1111/j.1476-5381.1959.tb00934.x | url = }}</ref>

The drug produces [hypolocomotion](/source/hypolocomotion) in rodents.<ref name="AbieroRyuBotanas2020" /> In addition, it induces the [head-twitch response](/source/head-twitch_response), a behavioral proxy of [psychedelic](/source/psychedelic_drug) effects, in rodents.<ref name="AbieroRyuBotanas2020" /> This was blocked by the serotonin 5-HT<sub>2A</sub> receptor [antagonist](/source/receptor_antagonist) [ketanserin](/source/ketanserin).<ref name="AbieroRyuBotanas2020" /> Hence, the drug may have [hallucinogen](/source/hallucinogen)ic effects in humans.<ref name="AbieroRyuBotanas2020" /> Conversely, pip-T did not produce [conditioned place preference](/source/conditioned_place_preference) (CPP) and was not [self-administered](/source/self-administration), suggesting that it lacks [reinforcing](/source/positive_reinforcement) properties and [misuse potential](/source/misuse_potential), similarly to most other tryptamines.<ref name="AbieroRyuBotanas2020" />

==Chemistry==
===Synthesis===
The [chemical synthesis](/source/chemical_synthesis) of pip-T has been described.<ref name="TiHKAL" />

===Analogues===
[Analogue](/source/Structural_analog)s of pip-T include [5-MeO-pip-T](/source/5-MeO-pip-T), [10,11-secoergoline](/source/10%2C11-secoergoline) (α,''N''-Pip-T), [pyr-T](/source/pyr-T), [MPMI](/source/MPMI_(drug)), [SN-22](/source/SN-22), [RU-24,969](/source/RU-24%2C969), and [EMD-386088](/source/EMD-386088), among others.

====mor-Tryptamine====
thumb|left|150px|class=skin-invert-image|mor-Tryptamine structure.

mor-Tryptamine, or mor-T, also known as 3-(2-morpholinoethyl)indole, is the [analogue](/source/structural_analog) of pip-T with the [piperidine](/source/piperidine) [ring](/source/ring_(chemistry)) replaced with a [morpholine](/source/morpholine) ring.<ref name="TiHKAL" /> It was briefly described by [Alexander Shulgin](/source/Alexander_Shulgin) in his book ''[TiHKAL](/source/TiHKAL)'' (''Tryptamines I Have Known and Loved''), including its [chemical synthesis](/source/chemical_synthesis).<ref name="TiHKAL" /> The drug was tested by [intramuscular injection](/source/intramuscular_injection) of 30{{nbsp}}mg as the [fumarate](/source/fumarate) [salt](/source/salt_(chemistry)), but produced no effects whatsoever.<ref name="TiHKAL" /> Accordingly, mor-T was completely inactive as a [serotonin receptor agonist](/source/serotonin_receptor_agonist) in the rat uterus and rat stomach strip.<ref name="BarlowKhan1959" /> The 5-[methoxy](/source/methoxy_group) [derivative](/source/chemical_derivative) of mor-T, [5-MeO-mor-T](/source/5-MeO-mor-T), is also known, but is not known to have been tested.<ref name="TiHKAL" />

==History==
Pip-T was first described in the [scientific literature](/source/scientific_literature) by 1959<ref name="BarlowKhan1959" /> and was more thoroughly characterized in 1990<ref name="Nichols2018" /><ref name="McKennaRepke1990" /> and 2020.<ref name="AbieroRyuBotanas2020" />

==See also==
* [Substituted tryptamine](/source/Substituted_tryptamine)
* [Cyclized tryptamine](/source/Cyclized_tryptamine)

==References==
{{Reflist}}

==External links==
* [https://isomerdesign.com/pihkal/explore/5189 pip-T - Isomer Design]

{{Psychedelics}}
{{Serotonin receptor modulators}}
{{Tryptamines}}

Category:N,N-Dialkyltryptamines
Category:Piperidines
Category:Psychedelic tryptamines
Category:Serotonin receptor modulators

---
Adapted from the Wikipedia article [Pip-Tryptamine](https://en.wikipedia.org/wiki/Pip-Tryptamine) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Pip-Tryptamine?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.
